LT3359564T - Antikūnai, kurie stipriai neutralizuoja hepatito b virusą, ir jų panaudojimas - Google Patents
Antikūnai, kurie stipriai neutralizuoja hepatito b virusą, ir jų panaudojimasInfo
- Publication number
- LT3359564T LT3359564T LTEP16779075.7T LT16779075T LT3359564T LT 3359564 T LT3359564 T LT 3359564T LT 16779075 T LT16779075 T LT 16779075T LT 3359564 T LT3359564 T LT 3359564T
- Authority
- LT
- Lithuania
- Prior art keywords
- antibodies
- virus
- potently neutralize
- neutralize hepatitis
- hepatitis
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/001970 WO2017059878A1 (en) | 2015-10-07 | 2015-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| PCT/EP2016/074114 WO2017060504A1 (en) | 2015-10-07 | 2016-10-07 | Antibodies that potently neutralize hepatitis b virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3359564T true LT3359564T (lt) | 2020-10-26 |
Family
ID=54330711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP16779075.7T LT3359564T (lt) | 2015-10-07 | 2016-10-07 | Antikūnai, kurie stipriai neutralizuoja hepatito b virusą, ir jų panaudojimas |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10683344B2 (enExample) |
| EP (2) | EP3753949A1 (enExample) |
| JP (4) | JP6869968B2 (enExample) |
| KR (1) | KR102725168B1 (enExample) |
| CN (3) | CN114539392B (enExample) |
| AU (1) | AU2016334735B2 (enExample) |
| BR (1) | BR112018002406A2 (enExample) |
| CA (1) | CA2993745A1 (enExample) |
| CY (1) | CY1123462T1 (enExample) |
| DK (1) | DK3359564T3 (enExample) |
| EA (1) | EA038301B1 (enExample) |
| ES (1) | ES2813927T3 (enExample) |
| HR (1) | HRP20201345T1 (enExample) |
| HU (1) | HUE050231T2 (enExample) |
| IL (1) | IL258326B (enExample) |
| LT (1) | LT3359564T (enExample) |
| MX (1) | MX2018004127A (enExample) |
| MY (1) | MY187161A (enExample) |
| PH (1) | PH12018500199A1 (enExample) |
| PL (1) | PL3359564T3 (enExample) |
| PT (1) | PT3359564T (enExample) |
| SI (1) | SI3359564T1 (enExample) |
| WO (2) | WO2017059878A1 (enExample) |
| ZA (1) | ZA201800710B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017059878A1 (en) | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
| CN112513063A (zh) | 2018-05-10 | 2021-03-16 | 克莱尔博治疗有限公司 | 用于治疗乙型肝炎感染的方法和组合物 |
| CN112770772A (zh) * | 2018-05-16 | 2021-05-07 | 长庚医疗财团法人林口长庚纪念医院 | 新型富亮氨酸重复神经元蛋白1(lrrn1)抗体和其用途 |
| JP7490574B2 (ja) * | 2018-05-31 | 2024-05-27 | ノバルティス アーゲー | Ｂ型肝炎抗体 |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| US12304946B2 (en) * | 2018-12-19 | 2025-05-20 | Humabs Biomed Sa | Antibodies that neutralize hepatitis B virus and uses thereof |
| DK3897672T5 (da) | 2018-12-20 | 2024-08-05 | Vir Biotechnology Inc | Hbv kombinationsbehandling |
| KR102084912B1 (ko) * | 2019-01-17 | 2020-03-05 | 주식회사 녹십자 | B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체 |
| JP2022542035A (ja) * | 2019-07-20 | 2022-09-29 | フアフイ ヘルス リミテッド | 抗ｐｒｅ－ｓ１ ｈｂｖ抗体を用いるｈｂｖ感染症の治療方法 |
| NZ785788A (en) | 2019-08-29 | 2025-09-26 | Vir Biotechnology Inc | Antibody compositions and methods for treating hepatitis b virus infection |
| CN113717283B (zh) * | 2020-05-25 | 2023-05-26 | 厦门万泰凯瑞生物技术有限公司 | 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用 |
| KR20230034978A (ko) * | 2020-06-02 | 2023-03-10 | 가부시키가이샤 알씨엠지 | Hbv의 항rna 바이러스 입자 항체 |
| CN115697489A (zh) * | 2020-06-08 | 2023-02-03 | 豪夫迈·罗氏有限公司 | 抗hbv抗体及其使用方法 |
| JP2023531682A (ja) * | 2020-06-22 | 2023-07-25 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Ｄ型肝炎ウイルス感染の処置のための組成物および方法 |
| TW202208422A (zh) * | 2020-06-24 | 2022-03-01 | 美商維爾生物科技股份有限公司 | 經工程化之b型肝炎病毒中和抗體及其用途 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4284428A1 (en) | 2021-01-26 | 2023-12-06 | VIR Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
| CN113234144B (zh) * | 2021-05-26 | 2022-02-25 | 武汉工程大学 | 一种人源性抗乙肝表面抗原的单链抗体、制剂、编码基因、载体质粒及宿主细胞 |
| WO2023287352A2 (en) * | 2021-07-15 | 2023-01-19 | National University Of Singapore | Anti-hbv antibodies and uses thereof |
| CN113777312B (zh) * | 2021-09-03 | 2024-02-02 | 普十生物科技(北京)有限公司 | 乙肝抗体片段的制备方法、乙肝抗体片段、试剂盒及应用 |
| US20240391979A1 (en) * | 2021-09-13 | 2024-11-28 | Achelois Biopharma, Inc. | Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use |
| JP2025501594A (ja) * | 2021-12-21 | 2025-01-22 | エイチビーヴイテック・エルエルシー | Ｂ型肝炎ウイルスｃｃｃＤＮＡ及びｒｃＤＮＡを排除するための方法、並びにその方法で使用されるＢ型肝炎薬物 |
| AR129399A1 (es) | 2022-05-23 | 2024-08-21 | Vir Biotechnology Inc | Anticuerpos diseñados neutralizantes del virus de la hepatitis b y usos de los mismos |
| CN116162153B (zh) * | 2022-09-01 | 2024-09-10 | 复旦大学附属中山医院 | 一种乙肝病毒表面抗原的单克隆抗体及其应用 |
| CN118725092B (zh) * | 2023-03-28 | 2025-08-12 | 东莞市朋志生物科技有限公司 | 抗HBs-Ag抗体、检测HBs-Ag的试剂和试剂盒 |
| WO2024249683A2 (en) * | 2023-05-31 | 2024-12-05 | Bluejay Therapeutics, Inc. | Anti-hbsag antibody for treatment of chronic hepatitis d |
| CN119143869A (zh) * | 2023-06-16 | 2024-12-17 | 复旦大学 | 乙肝病毒表面抗体及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| CA2251904A1 (en) | 1996-04-18 | 1997-10-23 | Abbott Laboratories | An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof |
| GB9608626D0 (en) * | 1996-04-25 | 1996-07-03 | Univ College Of London | Hepatitis b monoclonal antibodies |
| CA2274585A1 (en) * | 1996-12-30 | 1998-07-09 | Innogenetics N.V. | Annexin v-binding polypeptides derived from hbsag and their uses |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
| US20110097270A1 (en) * | 2005-01-14 | 2011-04-28 | Schofield Darren J | Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus |
| KR20100021601A (ko) | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| KR20090056537A (ko) * | 2007-11-30 | 2009-06-03 | 주식회사 녹십자 | Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물 |
| CN102282170B (zh) | 2008-10-22 | 2015-04-08 | 生物医学研究所 | 从浆细胞产生抗体的方法 |
| IN2015DN01087A (enExample) * | 2012-08-30 | 2015-06-26 | Replicor Inc | |
| CN104955837A (zh) * | 2012-11-12 | 2015-09-30 | 海德堡吕布莱希特-卡尔斯大学 | Hbv和/或hdv易感细胞、细胞系和非人动物的开发 |
| SG11201605691VA (en) * | 2014-01-16 | 2016-08-30 | Mario Umberto Francesco Mondelli | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen |
| WO2017059878A1 (en) * | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Antibodies that potently neutralize hepatitis b virus and uses thereof |
-
2015
- 2015-10-07 WO PCT/EP2015/001970 patent/WO2017059878A1/en not_active Ceased
-
2016
- 2016-10-07 AU AU2016334735A patent/AU2016334735B2/en active Active
- 2016-10-07 MY MYPI2018700678A patent/MY187161A/en unknown
- 2016-10-07 BR BR112018002406-6A patent/BR112018002406A2/pt not_active Application Discontinuation
- 2016-10-07 DK DK16779075.7T patent/DK3359564T3/da active
- 2016-10-07 EP EP20177206.8A patent/EP3753949A1/en active Pending
- 2016-10-07 PL PL16779075T patent/PL3359564T3/pl unknown
- 2016-10-07 WO PCT/EP2016/074114 patent/WO2017060504A1/en not_active Ceased
- 2016-10-07 JP JP2018514962A patent/JP6869968B2/ja active Active
- 2016-10-07 EA EA201890874A patent/EA038301B1/ru unknown
- 2016-10-07 HR HRP20201345TT patent/HRP20201345T1/hr unknown
- 2016-10-07 CN CN202210187026.6A patent/CN114539392B/zh active Active
- 2016-10-07 ES ES16779075T patent/ES2813927T3/es active Active
- 2016-10-07 LT LTEP16779075.7T patent/LT3359564T/lt unknown
- 2016-10-07 HU HUE16779075A patent/HUE050231T2/hu unknown
- 2016-10-07 US US15/766,703 patent/US10683344B2/en active Active
- 2016-10-07 SI SI201630896T patent/SI3359564T1/sl unknown
- 2016-10-07 PT PT167790757T patent/PT3359564T/pt unknown
- 2016-10-07 EP EP16779075.7A patent/EP3359564B1/en active Active
- 2016-10-07 KR KR1020187012979A patent/KR102725168B1/ko active Active
- 2016-10-07 CN CN202210185497.3A patent/CN114539391A/zh active Pending
- 2016-10-07 MX MX2018004127A patent/MX2018004127A/es unknown
- 2016-10-07 CN CN201680055161.8A patent/CN108137675B/zh active Active
- 2016-10-07 CA CA2993745A patent/CA2993745A1/en active Pending
-
2018
- 2018-01-25 PH PH12018500199A patent/PH12018500199A1/en unknown
- 2018-02-02 ZA ZA2018/00710A patent/ZA201800710B/en unknown
- 2018-03-25 IL IL258326A patent/IL258326B/en unknown
-
2020
- 2020-04-30 US US16/864,087 patent/US11390664B2/en active Active
- 2020-08-26 CY CY20201100795T patent/CY1123462T1/el unknown
-
2021
- 2021-04-14 JP JP2021068062A patent/JP7171809B2/ja active Active
-
2022
- 2022-07-18 US US17/867,466 patent/US12037381B2/en active Active
- 2022-11-02 JP JP2022175909A patent/JP2023011809A/ja not_active Withdrawn
-
2024
- 2024-05-01 JP JP2024074160A patent/JP2024097078A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258326B (en) | Antibodies that neutralize the hepatitis b virus in potency and their uses | |
| IL283321A (en) | Antibodies against muc16 and their uses | |
| IL258284A (en) | Anti-Lag 3 antibodies and their uses | |
| IL255961B (en) | Anti-cd40 antibodies and uses thereof | |
| ZA201800536B (en) | Il-8-binding antibodies and uses thereof | |
| IL257263A (en) | Antibodies against angptl8 and their use | |
| HUE056243T2 (hu) | Emberi immunhiányt okozó vírust semlegesítõ ellenanyagok | |
| SG11201803474UA (en) | Vaccines against hepatitis b virus | |
| IL254954A0 (en) | Anti-pacap antibodies and their uses | |
| IL249660B (en) | Methods for treating hepatitis b virus and hepatitis d virus infections | |
| PT3292154T (pt) | Anticorpos anti-her3 humano e seus usos | |
| GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof | |
| PL3220947T3 (pl) | Przeciwciała silnie neutralizujące wirusa wścieklizny i inne lyssawirusy oraz ich zastosowanie | |
| IL267785A (en) | virus | |
| GB201702193D0 (en) | Hepatitis E virus vaccine | |
| GB201600382D0 (en) | Engineered virus | |
| GB201716047D0 (en) | Virus | |
| GB201708779D0 (en) | Virus and method | |
| GB201708778D0 (en) | Virus and method | |
| GB201600380D0 (en) | Modified virus | |
| GB201700259D0 (en) | Virus |